Volume 11 Issue 2, May 2017

Nanowear Inc. has developed next-generation nanosensors for applications in health care and beyond. Building on its first US Food and Drug Administration (FDA) 510(k) clearance for an undergarment that captures multichannel electrocardiograms, Nanowear is now developing a garment to monitor congestive heart failure.

Alcon, in partnership with TrueVision 3D Surgical, has launched NGENUITY 3D, a complete digital solution for vitreoretinal surgery that uses an ultra-fast high-definition digital camera to provide an unparalleled three-dimensional view of the retina. The system is designed to improve the visualization of anatomy and pathology, reduce light exposure to the eye, and improve surgeon ergonomics.

By applying its unique epitope-identification platform to develop candidate antibodies targeting amyloid-β (Aβ) prions, in addition to developing its own companion diagnostics, ProMIS Neurosciences is working to provide a personalized overall approach to the treatment of central nervous system (CNS) diseases.

Bioelectronic medicine is on the cusp of becoming a new way to treat disease. The field’s potential to provide new treatment approaches using electric pulses to activate mechanisms in the body has attracted investments from companies including GlaxoSmithKline (GSK) and Google.

Diagnostics for applications in oncology—particularly immuno-oncology—continued to be the most common focus of dealmaking in the past 12 months, while deals related to Alzheimer’s disease and infectious disease threats such as Zika virus infection were also prominent.

Osiris Therapeutics, a regenerative medicine company with products for wound care, orthopedics and sports medicine, has developed Prestige Lyotechnology, a proprietary method to preserve living cells and tissues at ambient temperature.

BioMedica Diagnostics focuses on excellence in the thrombosis and hemostasis market, and takes a truly collaborative approach when sharing its expertise with international partners to enable them to achieve their objectives.

Clarity Pharmaceuticals leverages a powerful imaging technique called positron emission tomography (PET), and the perfect pairing of copper isotopes, to develop next-generation radiopharmaceuticals for diagnosing and treating cancer and other life-threatening diseases. This approach allows development of innovative ‘theranostic’ products.

Established in 1997 in Sydney, Australia, Five Corners is a privately owned clinical research organization (CRO) that provides contract services to manufacturers and distributors of medical technologies that wish to conduct clinical research in Australia and New Zealand.

Switzerland-based G-ray has identified a unique covalent bonding approach able to facilitate germanium absorbers for x-ray applications in the field of medical imaging and beyond.

Tumor-treating fields (TTFields) use electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. Novocure has launched Optune, its first TTFields delivery system, for the treatment of glioblastoma multiforme and potentially other solid tumor indications.